Syndax Pharmaceuticals (SNDX) Financials

$20.10 +0.14 (+0.70%)

As of 05/5/2026 04:00 PM Eastern

Annual Income Statements for Syndax Pharmaceuticals

This table shows Syndax Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-104	-47	-61	-74	-56	-77	25	-149	-209	-319	-285
Consolidated Net Income / (Loss)	-24	-44	-61	-74	-56	-73	25	-149	-209	-319	-285
Net Income / (Loss) Continuing Operations	-24	-44	-61	-74	-56	-73	25	-149	-209	-319	-285
Total Pre-Tax Income	-24	-44	-61	-74	-56	-73	25	-149	-209	-319	-285
Total Operating Income	-21	-44	-62	-76	-58	-71	26	-152	-230	-340	-273
Total Gross Profit	0.63	1.22	2.11	1.52	1.52	1.52	140	0.00	0.00	23	165
Total Revenue	0.63	1.22	2.11	1.52	1.52	1.52	140	0.00	0.00	24	172
Operating Revenue	0.63	1.22	2.11	1.52	1.52	1.52	140	0.00	0.00	24	172
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.83	6.97
Operating Cost of Revenue	-	-	-	-	-	-	-	0.00	0.00	0.83	6.97
Total Operating Expenses	21	45	64	77	59	73	113	152	230	363	438
Selling, General & Admin Expense	12	13	16	17	16	23	25	33	67	121	180
Research & Development Expense	9.55	32	48	60	43	50	88	118	163	242	259
Total Other Income / (Expense), net	-3.61	-0.71	1.15	1.92	1.49	-1.74	-1.29	2.42	21	21	-12
Interest Expense	-	-	-	0.00	0.00	2.36	1.90	3.14	0.21	-0.00	34
Interest & Investment Income	-1.41	0.96	1.42	1.94	1.57	0.84	0.40	5.87	21	26	23
Other Income / (Expense), net	-2.19	-1.66	-0.27	-0.03	-0.08	-0.22	0.20	-0.32	-0.36	-5.18	-1.28
Basic Earnings per Share	($1,519.27)	($3.22)	($2.90)	($2.92)	($1.84)	($1.87)	$0.48	($2.46)	($2.98)	($3.72)	($3.29)
Weighted Average Basic Shares Outstanding	68.35K	14.62M	21.00M	25.37M	30.49M	41.31M	52.06M	60.76M	70.37M	85.62M	86.63M
Diluted Earnings per Share	($1,519.27)	($3.22)	($2.90)	($2.92)	($1.84)	($1.87)	$0.46	($2.46)	($2.98)	($3.72)	($3.29)
Weighted Average Diluted Shares Outstanding	68.35K	14.62M	21.00M	25.37M	30.49M	41.31M	53.62M	60.76M	70.37M	85.62M	86.63M
Weighted Average Basic & Diluted Shares Outstanding	68.35K	14.62M	21.00M	25.37M	30.49M	41.31M	55.01M	68.44K	84.97M	86.02M	88.20M

This table shows Syndax Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-51	-72	-72	-68	-84	-94	-85	-72	-61	-68	-43
Consolidated Net Income / (Loss)	-51	-72	-72	-68	-84	-94	-85	-72	-61	-68	-43
Net Income / (Loss) Continuing Operations	-51	-72	-72	-68	-84	-94	-85	-72	-61	-68	-43
Total Pre-Tax Income	-51	-72	-72	-68	-84	-94	-85	-72	-61	-68	-43
Total Operating Income	-56	-78	-80	-74	-90	-96	-84	-69	-57	-63	-34
Total Gross Profit	0.00	-	0.00	3.50	13	7.68	19	37	44	66	62
Total Revenue	0.00	-	0.00	3.50	13	7.68	20	38	46	68	65
Operating Revenue	0.00	-	0.00	3.50	13	7.68	20	38	46	68	65
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.89	1.28	2.10	2.71	2.63
Operating Cost of Revenue	-	-	0.00	0.00	0.00	-	0.89	1.28	2.10	2.71	2.63
Total Operating Expenses	56	78	80	78	102	103	103	106	101	128	96
Selling, General & Admin Expense	17	23	23	29	31	38	41	44	45	50	38
Research & Development Expense	39	55	56	49	71	66	62	62	56	79	59
Other Special Charges / (Income)	-	-	0.00	0.00	-	-	0.25	0.00	-	-	0.00
Total Other Income / (Expense), net	5.21	5.43	7.11	6.15	5.45	2.44	-1.09	-2.49	-3.29	-5.47	-8.47
Interest Expense	0.07	0.06	0.06	0.05	0.02	4.81	8.05	0.00	0.00	26	12
Interest & Investment Income	5.35	5.55	7.26	6.28	5.44	7.11	7.18	5.95	5.27	4.33	3.56
Other Income / (Expense), net	-0.07	-0.06	-0.09	-0.09	0.03	-	-0.22	-8.44	-8.56	16	-0.19
Basic Earnings per Share	($0.73)	($1.02)	($0.85)	($0.80)	($0.98)	($1.09)	($0.98)	($0.83)	($0.70)	($0.78)	($0.48)
Weighted Average Basic Shares Outstanding	69.86M	70.37M	85.21M	85.27M	85.43M	85.62M	86.17M	86.34M	86.62M	86.63M	88.26M
Diluted Earnings per Share	($0.73)	($1.02)	($0.85)	($0.80)	($0.98)	($1.09)	($0.98)	($0.83)	($0.70)	($0.78)	($0.48)
Weighted Average Diluted Shares Outstanding	69.86M	70.37M	85.21M	85.27M	85.43M	85.62M	86.17M	86.34M	86.62M	86.63M	88.26M
Weighted Average Basic & Diluted Shares Outstanding	69.64M	84.97M	84.99M	85.10M	-	86.02M	86.05M	86.14M	86.91M	88.20M	88.61M

This table details how cash moves in and out of Syndax Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	13	0.76	11	-1.40	-9.26	91	107	-148	221	-141	-19
Net Cash From Operating Activities	-2.43	-35	-47	-69	-51	-71	29	-134	-161	-275	-323
Net Cash From Continuing Operating Activities	-2.43	-35	-47	-69	-51	-72	29	-135	-161	-275	-323
Net Income / (Loss) Continuing Operations	-24	-44	-61	-74	-56	-73	25	-149	-209	-319	-285
Consolidated Net Income / (Loss)	-24	-44	-61	-74	-56	-73	25	-149	-209	-319	-285
Depreciation Expense	0.02	0.09	0.08	0.08	0.09	-	-	-	0.01	0.01	0.01
Amortization Expense	1.07	-0.13	-0.22	-0.56	-0.78	-	0.64	-3.38	-15	-13	-11
Non-Cash Adjustments To Reconcile Net Income	6.05	6.44	5.44	6.21	6.36	9.06	13	13	42	56	9.14
Changes in Operating Assets and Liabilities, net	15	2.92	8.33	-0.30	-0.24	-7.93	-9.60	5.00	21	1.27	-36
Net Cash From Investing Activities	-62	-18	-17	51	13	-143	-41	-186	118	-220	290
Net Cash From Continuing Investing Activities	-62	-18	-17	51	13	-143	-41	-186	118	-220	290
Purchase of Property, Plant & Equipment	-0.05	-0.26	-0.08	-0.19	0.00	0.00	-0.13	-	0.00	0.00	-0.19
Purchase of Investments	-102	-158	-152	-79	-104	-279	-295	-495	-355	-557	-196
Sale and/or Maturity of Investments	41	140	135	130	117	136	254	309	472	337	486
Net Cash From Financing Activities	77	54	76	16	29	304	118	172	264	353	14
Net Cash From Continuing Financing Activities	77	54	76	16	29	304	118	172	264	353	14
Issuance of Common Equity	-	52	0.10	16	28	278	112	182	259	1.72	1.54
Other Financing Activities, net	0.19	2.06	76	0.03	0.18	6.63	6.34	-9.54	5.13	352	12
Cash Interest Paid	-	-	-	-	-	-	-	2.06	0.00	0.00	0.00

This table details how cash moves in and out of Syndax Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-2.73	201	-181	-9.22	28	21	-0.09	-45	8.17	18	-4.04
Net Cash From Operating Activities	-45	-41	-84	-72	-62	-57	-95	-88	-71	-69	-50
Net Cash From Continuing Operating Activities	-45	-42	-84	-71	-61	-59	-95	-88	-71	-70	-50
Net Income / (Loss) Continuing Operations	-51	-72	-72	-68	-84	-94	-85	-72	-61	-68	-43
Consolidated Net Income / (Loss)	-51	-72	-72	-68	-84	-94	-85	-72	-61	-68	-43
Depreciation Expense	-	-	-	-	-	-	0.00	-	-	0.00	0.00
Amortization Expense	-3.66	-3.46	-3.82	-3.65	-3.06	-2.91	-3.49	-3.16	-2.35	-1.53	-0.81
Non-Cash Adjustments To Reconcile Net Income	4.59	19	9.14	6.01	16	25	3.56	-11	12	3.64	15
Changes in Operating Assets and Liabilities, net	5.49	15	-17	-5.63	10	13	-10	-2.25	-20	-3.75	-22
Net Cash From Investing Activities	40	-16	-99	62	87	-269	94	42	72	82	38
Net Cash From Continuing Investing Activities	40	-16	-99	62	87	-269	94	42	72	82	38
Purchase of Property, Plant & Equipment	-	-	-	-	-	-	0.00	-	-	-0.06	0.00
Purchase of Investments	-83	-129	-167	-	-13	-376	-11	-92	-30	-63	-39
Sale and/or Maturity of Investments	123	113	68	62	100	107	105	134	103	145	78
Net Cash From Financing Activities	1.85	258	2.17	0.68	3.10	347	0.93	0.55	6.28	5.92	7.92
Net Cash From Continuing Financing Activities	1.85	258	2.17	0.68	3.10	347	0.93	0.55	6.28	5.92	7.92
Issuance of Common Equity	0.26	258	0.31	0.24	0.54	0.63	0.55	0.47	-0.08	0.61	0.46
Other Financing Activities, net	1.59	0.11	1.86	0.44	2.56	347	0.39	0.08	6.36	5.31	7.46

This table presents Syndax Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	90	109	137	84	64	301	450	497	613	725	530
Total Current Assets	88	109	133	83	62	299	448	490	581	603	528
Cash & Equivalents	23	24	35	34	25	115	222	74	295	154	135
Short-Term Investments	63	81	95	47	35	178	218	401	275	419	259
Accounts Receivable	-	-	-	-	-	-	-	-	0.00	11	44
Inventories, net	-	-	-	-	-	-	-	-	0.00	0.37	33
Prepaid Expenses	1.46	3.03	3.36	2.33	2.56	5.68	1.45	1.92	3.29	8.54	13
Other Current Assets	-	-	-	-	-	-	6.89	12	6.89	10	43
Plant, Property, & Equipment, net	0.09	0.26	0.27	0.37	0.28	0.19	0.28	0.02	0.01	0.00	0.18
Total Noncurrent Assets	1.81	0.24	3.48	0.22	0.91	1.56	0.98	7.43	32	122	1.44
Long-Term Investments	-	-	3.25	-	-	-	0.00	5.47	30	120	0.00
Other Noncurrent Operating Assets	1.81	0.24	0.23	0.22	0.91	1.56	0.98	1.96	2.17	2.24	1.44
Total Liabilities & Shareholders' Equity	90	109	137	84	64	301	450	497	613	725	530
Total Liabilities	23	25	33	31	32	48	41	30	59	437	465
Total Current Liabilities	4.85	10	16	16	18	19	21	29	58	104	120
Accounts Payable	1.45	2.38	2.23	1.44	6.18	3.51	5.67	4.35	9.96	12	17
Accrued Expenses	2.18	6.77	12	13	10	11	14	24	40	60	103
Other Current Liabilities	-	-	-	-	0.48	0.32	0.55	0.44	8.28	20	0.47
Total Noncurrent Liabilities	18	15	17	15	14	30	21	0.72	0.59	335	345
Capital Lease Obligations	-	-	-	-	-	-	0.00	0.01	0.01	1.58	1.05
Other Noncurrent Operating Liabilities	2.92	0.29	0.31	0.14	0.42	0.10	0.71	0.71	0.58	333	344
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-252	84	104	53	32	252	408	467	554	288	65
Total Preferred & Common Equity	-252	84	104	53	32	252	408	467	554	288	65
Preferred Stock	7.23	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-260	84	104	53	32	252	408	467	554	288	65
Common Stock	0.00	389	471	492	527	821	952	1,161	1,456	1,509	1,571
Retained Earnings	-260	-305	-366	-439	-495	-569	-544	-693	-902	-1,221	-1,507
Accumulated Other Comprehensive Income / (Loss)	0.03	0.06	-0.14	-0.03	0.00	-0.00	0.05	-0.81	0.22	0.16	0.45

This table presents Syndax Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	360	460	431	399	543	477	426	641	596	552	473
Total Current Assets	358	442	409	381	454	446	415	549	532	530	471
Cash & Equivalents	71	58	97	95	115	105	133	154	109	117	131
Short-Term Investments	266	375	302	269	320	320	257	358	347	319	221
Accounts Receivable	-	-	-	-	-	-	-	19	23	25	38
Inventories, net	-	-	-	-	-	-	-	4.66	18	25	35
Prepaid Expenses	2.27	1.91	3.06	3.75	4.67	4.21	4.91	8.46	9.88	9.52	16
Other Current Assets	17	5.81	7.22	14	15	17	20	4.12	26	34	30
Plant, Property, & Equipment, net	0.02	0.02	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.13	0.18
Total Noncurrent Assets	2.03	18	22	18	89	31	11	92	64	22	1.31
Long-Term Investments	-	17	19	16	87	30	10	90	63	20	0.00
Other Noncurrent Operating Assets	2.03	1.74	2.76	2.54	1.71	1.37	0.97	2.02	1.85	1.69	1.31
Total Liabilities & Shareholders' Equity	360	460	431	399	543	477	426	641	596	552	473
Total Liabilities	22	24	31	40	51	43	59	426	439	436	431
Total Current Liabilities	21	24	30	39	51	42	59	95	113	114	86
Accounts Payable	7.12	8.06	11	6.05	8.81	12	4.90	10	17	14	11
Accrued Expenses	13	15	18	32	33	27	48	56	71	77	75
Other Current Liabilities	0.48	0.45	1.46	1.01	8.60	4.10	6.36	29	25	23	0.49
Total Noncurrent Liabilities	0.78	0.60	1.13	0.86	0.33	0.14	0.00	331	326	322	345
Capital Lease Obligations	0.01	-	0.02	0.01	0.01	0.00	0.00	1.45	-	1.19	0.91
Other Noncurrent Operating Liabilities	0.77	0.59	1.12	0.85	0.33	0.13	0.00	330	326	321	344
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	338	436	400	359	492	434	366	215	157	115	42
Total Preferred & Common Equity	338	436	400	359	492	434	366	215	157	115	42
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	338	436	400	359	492	434	366	215	157	115	42
Common Stock	994	1,170	1,179	1,190	1,467	1,478	1,493	1,521	1,535	1,553	1,591
Retained Earnings	-654	-734	-779	-830	-975	-1,043	-1,127	-1,306	-1,378	-1,439	-1,549
Accumulated Other Comprehensive Income / (Loss)	-1.61	-	-0.57	-0.46	-0.76	-0.82	0.37	0.53	0.29	0.53	0.01

This table displays calculated financial ratios and metrics derived from Syndax Pharmaceuticals' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	94.58%	72.79%	-28.04%	0.00%	0.00%	9,109.56%	-100.00%	0.00%	0.00%	627.84%
EBITDA Growth	-11.22%	-110.30%	-37.18%	-22.47%	23.67%	-22.87%	137.78%	-674.36%	-57.68%	-44.05%	20.48%
EBIT Growth	-16.20%	-100.08%	-36.97%	-21.99%	24.09%	-24.34%	136.88%	-675.55%	-51.45%	-47.48%	20.44%
NOPAT Growth	3.84%	-113.36%	-41.56%	-22.47%	24.17%	-24.13%	152.44%	-505.15%	-51.53%	-47.71%	19.60%
Net Income Growth	-21.64%	-84.39%	-36.72%	-21.64%	24.22%	-30.53%	134.07%	-699.13%	-40.19%	-52.25%	10.46%
EPS Growth	-235.36%	99.79%	9.94%	-0.69%	36.99%	-1.63%	124.60%	-634.78%	-21.14%	-24.83%	11.56%
Operating Cash Flow Growth	83.13%	-1,347.98%	-34.74%	-44.67%	26.15%	-40.80%	140.88%	-558.88%	-20.14%	-71.17%	-17.49%
Free Cash Flow Firm Growth	0.00%	-631.17%	-22.53%	-51.68%	26.01%	-43.00%	129.91%	-708.16%	-23.27%	-73.98%	-334.93%
Invested Capital Growth	0.00%	-7.54%	-35.92%	3.59%	-0.75%	25.92%	43.53%	-17.14%	-235.44%	-30.82%	15.99%
Revenue Q/Q Growth	0.00%	1.41%	72.79%	-34.89%	0.00%	0.00%	933.89%	-100.00%	0.00%	48.00%	54.51%
EBITDA Q/Q Growth	0.00%	-20.43%	-17.08%	0.22%	8.22%	-7.26%	130.23%	-1,012.46%	-18.16%	-5.28%	10.64%
EBIT Q/Q Growth	0.00%	-21.78%	-16.07%	0.27%	8.18%	-7.64%	129.51%	-988.26%	-18.67%	-5.68%	10.60%
NOPAT Q/Q Growth	0.00%	-17.32%	-15.57%	0.21%	8.18%	-8.60%	141.90%	-660.20%	-18.48%	-5.75%	11.02%
Net Income Q/Q Growth	0.00%	-14.27%	-15.78%	0.36%	7.94%	-9.62%	127.18%	-970.83%	-18.90%	-7.30%	8.39%
EPS Q/Q Growth	0.00%	96.25%	-152.17%	3.31%	13.21%	0.00%	125.41%	-24,700.00%	-15.06%	-1.92%	8.61%
Operating Cash Flow Q/Q Growth	0.00%	-21.08%	-5.12%	-3.51%	4.38%	-4.25%	133.40%	-1,227.19%	-12.98%	-6.20%	-3.89%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	-0.77%	-4.59%	2.27%	-2.24%	124.30%	-325.62%	-11.09%	-5.57%	-377.54%
Invested Capital Q/Q Growth	0.00%	2.49%	-20.96%	-9.99%	0.43%	-14.12%	-13.93%	-8,571.78%	-130.89%	-82.52%	2.96%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	0.00%	100.00%	95.96%
EBITDA Margin	-3,448.01%	-3,726.64%	-2,958.73%	-5,035.14%	-3,843.51%	-4,722.61%	19.37%	0.00%	0.00%	-1,491.14%	-165.29%
Operating Margin	-3,271.61%	-3,587.38%	-2,938.99%	-5,001.71%	-3,792.95%	-4,708.17%	18.77%	0.00%	0.00%	-1,434.43%	-158.45%
EBIT Margin	-3,621.21%	-3,723.61%	-2,951.76%	-5,003.49%	-3,798.15%	-4,722.61%	18.91%	0.00%	0.00%	-1,434.43%	-159.19%
Profit (Net Income) Margin	-3,846.73%	-3,645.25%	-2,884.35%	-4,875.48%	-3,694.59%	-4,822.54%	17.84%	0.00%	0.00%	-1,346.11%	-165.60%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.08%	100.00%
Interest Burden Percent	106.23%	97.90%	97.72%	97.44%	97.27%	102.12%	94.34%	98.20%	90.90%	93.77%	104.03%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-36.16%	-58.97%	-64.53%	-94.00%	-132.43%	-51.56%	7.55%	-34.10%	-40.98%	-75.69%	-161.83%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-25.26%	-45.68%	-50.55%	-68.65%	-78.15%	-39.35%	7.04%	0.00%	0.00%	-50.78%	-43.74%
Return on Assets (ROA)	-26.83%	-44.71%	-49.39%	-66.90%	-76.02%	-40.18%	6.64%	0.00%	0.00%	-47.66%	-45.50%
Return on Common Equity (ROCE)	140.77%	68.61%	-64.53%	-94.00%	-132.43%	-51.56%	7.55%	-34.10%	-40.98%	-75.69%	-161.83%
Return on Equity Simple (ROE_SIMPLE)	9.56%	-52.86%	-58.28%	-139.43%	-177.36%	-29.01%	6.10%	-31.95%	-37.78%	-110.63%	0.00%
Net Operating Profit after Tax (NOPAT)	-14	-31	-43	-53	-40	-50	26	-106	-161	-238	-191
NOPAT Margin	-2,290.13%	-2,511.16%	-2,057.30%	-3,501.20%	-2,655.06%	-3,295.72%	18.77%	0.00%	0.00%	-1,004.10%	-110.91%
Net Nonoperating Expense Percent (NNEP)	-22.56%	-14.41%	-14.60%	-19.45%	-22.40%	-13.92%	-0.37%	-9.56%	-8.95%	-17.06%	-17.55%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-22.72%	-29.04%	-37.63%	-295.77%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	4.04%
SG&A Expenses to Revenue	1,848.64%	1,091.89%	752.42%	1,139.55%	1,058.80%	1,483.52%	18.07%	0.00%	0.00%	510.47%	104.25%
R&D to Revenue	1,522.97%	2,595.49%	2,286.58%	3,962.16%	2,834.15%	3,324.65%	63.17%	0.00%	0.00%	1,020.47%	150.15%
Operating Expenses to Revenue	3,371.61%	3,687.38%	3,038.99%	5,101.71%	3,892.95%	4,808.17%	81.23%	0.00%	0.00%	1,530.94%	254.40%
Earnings before Interest and Taxes (EBIT)	-23	-45	-62	-76	-58	-72	26	-152	-230	-340	-274
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-22	-45	-62	-76	-58	-72	27	-155	-245	-353	-285
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	1.55	2.05	2.08	7.54	3.60	2.65	3.28	2.72	3.90	28.25
Price to Tangible Book Value (P/TBV)	0.00	1.55	2.05	2.08	7.54	3.60	2.65	3.28	2.72	3.90	28.25
Price to Revenue (P/Rev)	0.00	106.92	101.35	72.85	157.08	599.16	7.74	0.00	0.00	47.51	10.60
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	43.38	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.31%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	20.46	38.11	19.45	117.60	419.16	4.73	0.00	0.00	32.78	8.31
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	24.42	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	25.02	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	25.21	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	22.69	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	38.58	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.08	0.05	0.00	0.00	1.19	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.07	0.05	0.00	0.00	1.15	0.00
Financial Leverage	-1.30	-1.27	-1.27	-1.36	-1.66	-1.17	-1.05	-1.03	-1.06	-1.13	-3.05
Leverage Ratio	1.35	1.32	1.31	1.41	1.74	1.28	1.14	1.08	1.09	1.59	3.56
Compound Leverage Factor	1.43	1.29	1.28	1.37	1.69	1.31	1.07	1.06	0.99	1.49	3.70
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	7.39%	4.65%	0.00%	0.00%	54.40%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.84%	0.00%	0.00%	0.00%	1.92%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	6.55%	4.65%	0.00%	0.00%	52.48%	0.00%
Preferred Equity to Total Capital	10.84%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	478.44%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-389.29%	100.00%	100.00%	100.00%	100.00%	92.61%	95.35%	100.00%	100.00%	45.60%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	-0.28	0.74	0.00	0.00	-0.97	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	3.81	-15.52	3.10	2.45	0.99	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	-0.25	0.74	0.00	0.00	-0.94	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	-0.40	0.76	0.00	0.00	-1.45	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	5.46	-16.02	4.53	3.73	1.47	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	-0.36	0.76	0.00	0.00	-1.39	0.00
Altman Z-Score	0.00	-1.06	-0.29	-7.19	-8.58	8.95	15.66	29.02	13.11	-1.50	-2.09
Noncontrolling Interest Sharing Ratio	489.29%	216.36%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	18.16	10.47	8.45	5.18	3.39	15.84	21.68	16.85	10.00	5.82	4.40
Quick Ratio	17.84	10.16	8.23	5.02	3.25	15.53	21.27	16.37	9.82	5.64	3.65
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	5.49	-29	-36	-54	-40	-57	17	-104	-128	-223	-254
Operating Cash Flow to CapEx	-4,955.10%	-13,470.11%	-56,394.05%	-36,647.59%	0.00%	0.00%	22,582.17%	0.00%	0.00%	0.00%	-172,716.58%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	-24.31	9.02	-33.22	-617.58	-45.34	-7.51
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	-30.23	15.34	-42.61	-772.12	-55.77	-9.56
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-30.23	15.27	-42.54	-772.12	-55.77	-9.57
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.01	0.01	0.02	0.01	0.02	0.01	0.37	0.00	0.00	0.04	0.27
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.20
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.42
Fixed Asset Turnover	7.13	7.01	8.00	4.74	4.64	6.41	594.51	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.49
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	58.91
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	867.20
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	738.54
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	187.58
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-20	-21	-29	-28	-28	-21	-12	-14	-46	-61	-329
Invested Capital Turnover	-0.06	-0.06	-0.08	-0.05	-0.05	-0.06	-8.56	0.00	0.00	-0.44	-0.48
Increase / (Decrease) in Invested Capital	-20	-1.50	-7.67	1.04	-0.21	7.30	9.09	-2.02	-33	-14	63
Enterprise Value (EV)	0.00	25	80	30	178	636	661	1,051	904	776	1,432
Market Capitalization	0.00	130	214	111	238	909	1,081	1,533	1,505	1,125	1,826
Book Value per Share	($3,798.66)	$4.62	$4.28	$2.14	$1.16	$6.17	$8.27	$7.76	$7.96	$3.37	$0.74
Tangible Book Value per Share	($3,798.66)	$4.62	$4.28	$2.14	$1.16	$6.17	$8.27	$7.76	$7.96	$3.37	$0.74
Total Capital	67	84	104	53	32	272	428	467	554	632	65
Total Debt	0.00	0.00	0.00	0.00	0.00	20	20	0.01	0.01	344	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	18	20	0.01	0.01	332	0.00
Net Debt	-87	-105	-133	-81	-60	-273	-420	-481	-601	-349	-394
Capital Expenditures (CapEx)	0.05	0.26	0.08	0.19	0.00	0.00	0.13	-0.23	0.00	0.00	0.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-3.38	-7.34	-12	-14	-16	-11	-12	-15	-48	-61	14
Debt-free Net Working Capital (DFNWC)	83	98	118	67	44	282	428	461	523	512	408
Net Working Capital (NWC)	83	98	118	67	44	280	428	461	523	500	408
Net Nonoperating Expense (NNE)	9.76	14	17	21	16	23	1.29	43	48	81	94
Net Nonoperating Obligations (NNO)	-87	-105	-133	-81	-60	-273	-420	-481	-601	-349	-394
Total Depreciation and Amortization (D&A)	1.09	-0.04	-0.15	-0.48	-0.69	0.00	0.64	-3.38	-15	-13	-11
Debt-free, Cash-free Net Working Capital to Revenue	-539.55%	-601.39%	-589.94%	-907.78%	-1,049.90%	-718.72%	-8.83%	0.00%	0.00%	-258.70%	8.06%
Debt-free Net Working Capital to Revenue	13,263.16%	8,044.59%	5,580.83%	4,432.50%	2,898.02%	18,607.58%	306.15%	0.00%	0.00%	2,160.57%	236.70%
Net Working Capital to Revenue	13,263.16%	8,044.59%	5,580.83%	4,432.50%	2,898.02%	18,456.95%	306.15%	0.00%	0.00%	2,109.41%	236.70%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1,519.27)	($3.22)	($2.90)	($2.92)	($1.84)	$0.00	$0.48	($2.46)	($2.98)	($3.72)	($3.29)
Adjusted Weighted Average Basic Shares Outstanding	68.35K	18.24M	24.70M	25.00M	30.24M	0.00	52.06M	60.76M	70.37M	85.62M	86.63M
Adjusted Diluted Earnings per Share	($1,519.27)	($3.22)	($2.90)	($2.92)	($1.84)	$0.00	$0.46	($2.46)	($2.98)	($3.72)	($3.29)
Adjusted Weighted Average Diluted Shares Outstanding	68.35K	18.24M	24.70M	25.00M	30.24M	0.00	53.62M	60.76M	70.37M	85.62M	86.63M
Adjusted Basic & Diluted Earnings per Share	($1,519.27)	($3.22)	($2.90)	($2.92)	($1.84)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	68.35K	14.62M	21.00M	25.37M	30.49M	0.00	55.01M	68.44K	84.97M	86.02M	88.20M
Normalized Net Operating Profit after Tax (NOPAT)	-14	-31	-43	-53	-40	-50	18	-106	-161	-238	-191
Normalized NOPAT Margin	-2,290.13%	-2,511.16%	-2,057.30%	-3,501.20%	-2,655.06%	-3,295.72%	13.14%	0.00%	0.00%	-1,004.10%	-110.91%
Pre Tax Income Margin	-3,846.73%	-3,645.25%	-2,884.35%	-4,875.48%	-3,694.59%	-4,822.54%	17.84%	0.00%	0.00%	-1,345.06%	-165.60%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	-30.40	13.91	-48.48	-1,107.28	-68.91	-8.12
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	-21.21	13.81	-33.86	-773.88	-48.24	-5.66
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-30.40	13.85	-48.41	-1,107.28	-68.91	-8.13
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-21.21	13.74	-33.79	-773.88	-48.24	-5.66
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Syndax Pharmaceuticals' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	88,200,596.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	88,200,596.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-0.48
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	984.51%	266.97%	791.68%	223.64%
EBITDA Growth	-64.76%	-84.80%	-66.42%	-45.74%	-54.13%	-21.93%	-4.85%	-3.85%	26.21%	53.85%	59.77%
EBIT Growth	-59.22%	-85.47%	-72.44%	-49.29%	-58.71%	-23.61%	-5.50%	-4.70%	26.31%	54.03%	59.05%
NOPAT Growth	-60.37%	-85.34%	-72.80%	-49.39%	-58.95%	-23.69%	-5.34%	6.55%	35.89%	35.09%	59.17%
Net Income Growth	-44.47%	-84.91%	-76.04%	-52.56%	-64.48%	-29.94%	-17.19%	-5.56%	27.83%	27.77%	49.71%
EPS Growth	-25.86%	-61.90%	-44.07%	-25.00%	-34.25%	-6.86%	-15.29%	-3.75%	28.57%	28.44%	51.02%
Operating Cash Flow Growth	-56.44%	-80.61%	-112.98%	-102.55%	-39.57%	-38.79%	-13.90%	-22.54%	-13.18%	-21.08%	47.10%
Free Cash Flow Firm Growth	45.25%	19.64%	-93.85%	-271.76%	-157.83%	-141.47%	835.13%	684.32%	636.89%	-138.26%	-133.69%
Invested Capital Growth	-12,407.98%	-235.44%	-103.02%	-11.21%	-65.50%	-30.82%	-1,181.22%	-1,678.09%	-922.54%	15.99%	19.73%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	257.14%	-38.56%	160.96%	89.39%	20.85%	49.29%	-5.28%
EBITDA Q/Q Growth	-12.33%	-35.52%	-2.46%	6.56%	-18.80%	-7.21%	11.90%	7.45%	15.58%	29.55%	26.90%
EBIT Q/Q Growth	-13.36%	-38.18%	-2.10%	6.66%	-20.51%	-7.62%	12.85%	7.37%	15.18%	29.36%	26.23%
NOPAT Q/Q Growth	-13.44%	-38.24%	-2.06%	6.66%	-20.70%	-7.58%	13.08%	17.20%	17.20%	-8.92%	45.32%
Net Income Q/Q Growth	-14.64%	-41.70%	0.10%	5.99%	-23.60%	-11.94%	9.90%	15.32%	15.49%	-12.02%	37.26%
EPS Q/Q Growth	-14.06%	-39.73%	16.67%	5.88%	-22.50%	-11.22%	10.09%	15.31%	15.66%	-11.43%	38.46%
Operating Cash Flow Q/Q Growth	-26.24%	7.40%	-102.06%	14.25%	13.01%	7.92%	-65.82%	7.74%	19.66%	1.48%	27.55%
Free Cash Flow Firm Q/Q Growth	-43.20%	-14.56%	-83.39%	-23.57%	0.69%	-7.29%	658.31%	-1.78%	-8.75%	-140.02%	6.07%
Invested Capital Q/Q Growth	-10.07%	-130.89%	35.02%	32.65%	-63.79%	-82.52%	-536.35%	6.53%	5.81%	2.96%	6.04%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	100.00%	100.00%	100.00%	95.58%	96.63%	95.42%	96.05%	95.94%
EBITDA Margin	0.00%	0.00%	0.00%	-2,227.17%	-740.82%	-1,292.64%	-436.41%	-213.26%	-148.97%	-70.30%	-54.25%
Operating Margin	0.00%	0.00%	0.00%	-2,120.46%	-716.62%	-1,254.75%	-417.91%	-182.71%	-125.19%	-91.34%	-52.73%
EBIT Margin	0.00%	0.00%	0.00%	-2,122.91%	-716.36%	-1,254.75%	-419.01%	-204.94%	-143.85%	-68.07%	-53.02%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	-1,944.66%	-673.01%	-1,226.16%	-423.34%	-189.28%	-132.36%	-99.32%	-65.79%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.26%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	90.65%	92.96%	90.95%	91.60%	93.95%	97.46%	101.03%	92.36%	92.01%	145.92%	124.09%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-50.50%	-40.98%	-51.89%	-63.30%	-81.88%	-75.69%	-93.70%	-113.22%	-129.32%	-161.83%	-189.53%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	-16.36%	-27.78%	-44.42%	-30.95%	-29.86%	-32.83%	-18.70%	-20.68%
Return on Assets (ROA)	0.00%	0.00%	0.00%	-14.99%	-26.10%	-43.41%	-31.27%	-27.58%	-30.21%	-27.29%	-25.67%
Return on Common Equity (ROCE)	-50.50%	-40.98%	-51.91%	-63.30%	-81.88%	-75.69%	-93.70%	-113.22%	-129.32%	-161.83%	-189.53%
Return on Equity Simple (ROE_SIMPLE)	-49.02%	0.00%	-48.92%	-60.80%	-81.07%	0.00%	-154.01%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-39	-55	-56	-52	-63	-67	-59	-49	-40	-44	-24
NOPAT Margin	0.00%	0.00%	0.00%	-1,484.32%	-501.63%	-878.33%	-292.54%	-127.90%	-87.63%	-63.94%	-36.91%
Net Nonoperating Expense Percent (NNEP)	-3.26%	-3.32%	-3.44%	-3.69%	-5.50%	-5.63%	-4.67%	-4.79%	-4.80%	-4.51%	-3.94%
Return On Investment Capital (ROIC_SIMPLE)	-	-9.84%	-	-	-	-10.68%	-27.08%	-30.84%	-34.47%	-67.75%	-56.29%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	4.42%	3.37%	4.58%	3.95%	4.06%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	830.31%	248.85%	490.76%	204.73%	115.40%	97.92%	72.91%	57.95%
R&D to Revenue	0.00%	0.00%	0.00%	1,390.14%	567.77%	853.24%	307.53%	163.94%	122.69%	114.84%	90.72%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	2,220.46%	816.62%	1,344.00%	513.49%	279.34%	220.61%	187.38%	148.67%
Earnings before Interest and Taxes (EBIT)	-56	-78	-80	-74	-90	-96	-84	-78	-66	-47	-34
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-60	-81	-83	-78	-93	-99	-87	-81	-68	-48	-35
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.81	2.72	3.37	4.02	4.47	3.90	4.91	5.12	11.48	28.25	49.50
Price to Tangible Book Value (P/TBV)	2.81	2.72	3.37	4.02	4.47	3.90	4.91	5.12	11.48	28.25	49.50
Price to Revenue (P/Rev)	0.00	0.00	0.00	498.51	102.38	47.51	24.17	10.31	11.88	10.60	9.49
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	368.62	77.40	32.78	10.43	3.68	7.80	8.31	7.87
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	3.97	2.80	9.52	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	1.19	0.01	0.00	0.01	0.00	0.02
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	1.15	0.01	0.00	0.01	0.00	0.02
Financial Leverage	-1.03	-1.06	-1.05	-1.05	-1.07	-1.13	-1.59	-1.64	-1.77	-3.05	-3.71
Leverage Ratio	1.09	1.09	1.08	1.09	1.14	1.59	1.67	1.81	2.03	3.56	4.34
Compound Leverage Factor	0.99	1.01	0.98	1.00	1.07	1.55	1.69	1.67	1.87	5.19	5.38
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	54.40%	0.67%	0.00%	1.02%	0.00%	2.13%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	1.92%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	52.48%	0.67%	0.00%	1.02%	0.00%	2.13%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	45.60%	99.33%	100.00%	98.98%	100.00%	97.87%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	-0.97	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	1.83	2.45	1.87	1.50	1.19	0.99	1.68	0.00	1.43	0.00	1.51
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	-0.94	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	-1.45	-0.01	0.00	-0.01	0.00	-0.01
Net Debt to NOPAT	2.79	3.73	2.83	2.26	1.78	1.47	2.50	0.00	2.12	0.00	2.24
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	-1.39	-0.01	0.00	-0.01	0.00	-0.01
Altman Z-Score	12.77	13.93	17.34	22.02	13.19	-0.39	-0.88	-1.59	-1.12	-0.67	-0.52
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	-0.04%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.73	10.00	8.93	10.50	6.99	5.82	5.80	4.71	4.64	4.40	5.47
Quick Ratio	9.28	9.82	8.55	10.01	6.56	5.64	5.62	4.23	4.04	3.65	4.53
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-19	-22	-40	-50	-50	-53	297	292	266	-106	-100
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-124,085.71%	0.00%
Free Cash Flow to Firm to Interest Expense	-274.62	-349.56	-734.31	-1,109.05	-2,154.95	-11.06	36.88	72,904.48	0.00	-4.14	-8.44
Operating Cash Flow to Interest Expense	-637.90	-656.33	-1,519.05	-1,592.11	-2,709.65	-11.94	-11.82	-21,948.75	0.00	-2.70	-4.25
Operating Cash Flow Less CapEx to Interest Expense	-637.90	-656.33	-1,519.05	-1,592.11	-2,709.65	-11.94	-11.82	-21,948.75	0.00	-2.70	-4.25
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.01	0.04	0.04	0.07	0.15	0.23	0.27	0.39
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.20	7.53
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.42	0.44
Fixed Asset Turnover	0.00	0.00	0.00	466.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.09	0.15	0.46	0.49	0.83
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	58.91	48.48
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	867.20	829.23
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	3,888.38	2,439.04	801.39	738.54	437.31
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	-3,888.38	-2,439.04	-801.39	187.58	440.40
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-20	-46	-30	-20	-33	-61	-386	-360	-340	-329	-310
Invested Capital Turnover	0.00	0.00	0.00	-0.18	-0.60	-0.44	-0.21	-0.41	-0.60	-0.48	-0.62
Increase / (Decrease) in Invested Capital	-20	-33	-15	-2.04	-13	-14	-356	-340	-306	63	76
Enterprise Value (EV)	630	904	1,135	1,290	1,238	776	456	288	870	1,432	1,709
Market Capitalization	1,009	1,505	1,657	1,745	1,638	1,125	1,057	806	1,325	1,826	2,060
Book Value per Share	$5.17	$7.96	$5.77	$5.11	$4.31	$3.37	$2.50	$1.83	$1.34	$0.74	$0.47
Tangible Book Value per Share	$5.17	$7.96	$5.77	$5.11	$4.31	$3.37	$2.50	$1.83	$1.34	$0.74	$0.47
Total Capital	359	554	492	434	366	632	217	157	117	65	43
Total Debt	0.01	0.01	0.01	0.00	0.00	344	1.45	0.00	1.19	0.00	0.91
Total Long-Term Debt	0.01	0.01	0.01	0.00	0.00	332	1.45	0.00	1.19	0.00	0.91
Net Debt	-379	-601	-522	-455	-400	-349	-601	-518	-455	-394	-351
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-22	-48	-31	-22	-34	-61	-58	-37	-20	14	33
Debt-free Net Working Capital (DFNWC)	342	523	403	404	355	512	454	419	416	408	385
Net Working Capital (NWC)	342	523	403	404	355	500	454	419	416	408	385
Net Nonoperating Expense (NNE)	12	18	17	16	21	27	26	23	21	24	19
Net Nonoperating Obligations (NNO)	-379	-601	-522	-455	-400	-349	-601	-518	-455	-394	-351
Total Depreciation and Amortization (D&A)	-3.66	-3.46	-3.82	-3.65	-3.06	-2.91	-3.49	-3.16	-2.35	-1.53	-0.80
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	-614.66%	-213.59%	-258.70%	-132.65%	-46.74%	-18.23%	8.06%	15.17%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	11,530.97%	2,221.45%	2,160.57%	1,038.84%	535.54%	372.60%	236.70%	177.28%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	11,530.97%	2,221.45%	2,109.41%	1,038.84%	535.54%	372.60%	236.70%	177.28%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.73)	($1.02)	($0.85)	($0.80)	($0.98)	($1.09)	($0.98)	($0.83)	($0.70)	($0.78)	($0.48)
Adjusted Weighted Average Basic Shares Outstanding	69.86M	70.37M	85.21M	85.27M	85.43M	85.62M	86.17M	86.34M	86.62M	86.63M	88.26M
Adjusted Diluted Earnings per Share	($0.73)	($1.02)	($0.85)	($0.80)	($0.98)	($1.09)	($0.98)	($0.83)	($0.70)	($0.78)	($0.48)
Adjusted Weighted Average Diluted Shares Outstanding	69.86M	70.37M	85.21M	85.27M	85.43M	85.62M	86.17M	86.34M	86.62M	86.63M	88.26M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	69.64M	84.97M	84.99M	85.10M	0.00	86.02M	86.05M	86.14M	86.91M	88.20M	88.61M
Normalized Net Operating Profit after Tax (NOPAT)	-39	-55	-56	-52	-63	-67	-58	-49	-40	-44	-24
Normalized NOPAT Margin	0.00%	0.00%	0.00%	-1,484.32%	-501.63%	-878.33%	-291.67%	-127.90%	-87.63%	-63.94%	-36.91%
Pre Tax Income Margin	0.00%	0.00%	0.00%	-1,944.66%	-673.01%	-1,222.94%	-423.34%	-189.28%	-132.36%	-99.32%	-65.79%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-806.01	-1,237.48	-1,447.29	-1,651.16	-3,893.26	-20.05	-10.43	-19,448.25	0.00	-1.81	-2.90
NOPAT to Interest Expense	-563.55	-865.62	-1,012.00	-1,154.47	-2,726.26	-14.04	-7.28	-12,136.78	0.00	-1.70	-2.02
EBIT Less CapEx to Interest Expense	-806.01	-1,237.48	-1,447.29	-1,651.16	-3,893.26	-20.05	-10.43	-19,448.25	0.00	-1.81	-2.90
NOPAT Less CapEx to Interest Expense	-563.55	-865.62	-1,012.00	-1,154.47	-2,726.26	-14.04	-7.28	-12,136.78	0.00	-1.70	-2.02
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Here’s a concise, data-driven read on Syndax Pharmaceuticals (NASDAQ:SNDX) using quarterly numbers from the last four years. The focus is on trends in income statements, balance sheets, and cash flows, with a tone aimed at retail investors familiar with the basics of financial statements.

Q4 2025 revenue reached about $68.5 million, with a gross profit of roughly $65.8 million, implying a very strong gross margin around 96% for the quarter.
Across the latest quarters, gross margins have been in the mid-to-high 90s, signaling favorable product cost structure even as overall profitability remains negative due to operating expenses.
R&D expense remains the primary driver of cash burn, with RD expense around $78.6 million in Q4 2025, indicating continued pipeline investment rather than immediate profitability.
Operating cash flow stayed negative in Q4 2025 and in prior quarters, showing ongoing cash burn before financing and investing activities.
One-off investing and financing moves in Q4 2025 provided a modest liquidity lift (net cash from investing activities was a positive $81.6 million from investment sales/maturities, with a small financing influx), rather than a core improvement in operating cash flow.
Net income in Q4 2025 was -$68.0 million, continuing the recent pattern of quarterly losses driven by high R&D and SG&A spend.
Total operating expenses in Q4 2025 totaled $128.3 million, far exceeding revenue and producing a negative operating margin for the quarter.
Retained earnings were deeply negative (about -$1.44 billion as of Q3 2025), reflecting a long history of accumulated losses and ongoing equity erosion.
Total liabilities (~$436 million in Q3 2025) substantially exceed total equity (~$115 million), indicating a leveraged balance sheet that could pose challenges for liquidity if losses persist.
Net cash from continuing operating activities was negative in multiple periods (e.g., -$69.7 million in Q4 2025 and -$70.5 million in Q3 2025), underscoring persistent cash burn without sustained near-term cash generation.

05/06/26 05:26 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Syndax Pharmaceuticals' Financials

When does Syndax Pharmaceuticals' financial year end?

According to the most recent income statement we have on file, Syndax Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has Syndax Pharmaceuticals' net income changed over the last 10 years?

Syndax Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$285.42 million in 2025, rising from -$24.12 million in 2015. The previous period was -$318.76 million in 2024. Check out Syndax Pharmaceuticals' forecast to explore projected trends and price targets.

What is Syndax Pharmaceuticals' operating income?

Syndax Pharmaceuticals' total operating income in 2025 was -$273.08 million, based on the following breakdown:

Total Gross Profit: $165.38 million
Total Operating Expenses: $438.47 million

How has Syndax Pharmaceuticals' revenue changed over the last 10 years?

Over the last 10 years, Syndax Pharmaceuticals' total revenue changed from $627 thousand in 2015 to $172.35 million in 2025, a change of 27,388.4%.

How much debt does Syndax Pharmaceuticals have?

Syndax Pharmaceuticals' total liabilities were at $465.08 million at the end of 2025, a 6.5% increase from 2024, and a 1,904.2% increase since 2015.

How much cash does Syndax Pharmaceuticals have?

In the past 10 years, Syndax Pharmaceuticals' cash and equivalents has ranged from $23.18 million in 2015 to $295.39 million in 2023, and is currently $134.93 million as of their latest financial filing in 2025.

How has Syndax Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, Syndax Pharmaceuticals' book value per share changed from -3,798.66 in 2015 to 0.74 in 2025, a change of -100.0%.

Related Companies

Financial statements for NASDAQ:SNDX last updated on 5/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Syndax Pharmaceuticals (SNDX) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Syndax Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Syndax Pharmaceuticals (SNDX) Financials

Annual Income Statements for Syndax Pharmaceuticals

Quarterly Income Statements for Syndax Pharmaceuticals

Annual Cash Flow Statements for Syndax Pharmaceuticals

Quarterly Cash Flow Statements for Syndax Pharmaceuticals

Annual Balance Sheets for Syndax Pharmaceuticals

Quarterly Balance Sheets for Syndax Pharmaceuticals

Annual Metrics And Ratios for Syndax Pharmaceuticals

Quarterly Metrics And Ratios for Syndax Pharmaceuticals

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Syndax Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools